Table 2.
Percentage (with 95% confidence intervals) of subjects reporting solicited local (injection site) symptoms within 7 days after the first and after the second dose of H1N1 vaccine in adults aged 18 to 60 years and in adults >60 years
| Symptom | Intensity |
Group A Vaccinated on Day 0 and Day 21 |
Group B Vaccinated on Day 0 and Day 182 |
||
|---|---|---|---|---|---|
|
Dose 1% (95% CI) | |||||
| 18-60 years N = 92 | >60 years N = 90 | 18-60 years N = 70 | >60 years N = 52 | ||
|
Pain |
Any |
94.6 |
78.9 |
95.7 |
67.3 |
| (87.8-98.2) |
(69.0-86.8) |
(88.0-99.1) |
(52.9-79.7) |
||
| Grade 3* |
0.0 |
2.2 |
0.0 |
0.0 |
|
| (0.0-3.9) |
(0.3-7.8) |
(0.0-5.1) |
(0.0-6.8) |
||
|
Redness |
Any |
10.9 |
8.9 |
11.4 |
1.9 |
| (5.3-19.1) |
(3.9-16.8) |
(5.1-21.3) |
(0.0-10.3) |
||
| >100 mm |
0.0 |
0.0 |
0.0 |
0.0 |
|
| (0.0-3.9) |
(0.0-4.0) |
(0.0-5.1) |
(0.0-6.8) |
||
|
Swelling |
Any |
12.0 |
6.7 |
8.6 |
1.9 |
| (6.1-20.4) |
(2.5-13.9) |
(3.2-17.7) |
(0.0-10.3) |
||
| >100 mm |
0.0 |
0.0 |
0.0 |
0.0 |
|
| (0.0-3.9) |
(0.0-4.0) |
(0.0-5.1) |
(0.0-6.8) |
||
| |
|
Dose 2% (95% CI) |
|||
|
18-60 years N = 91 |
>60 years N = 85 |
18-60 years N = 60 |
>60 years N = 45 |
||
|
Pain |
Any |
87.9 |
72.9 |
90.0 |
57.8 |
| (79.4-93.8) |
(62.2-82.0) |
(79.5-96.2) |
(42.2-72.3) |
||
| Grade 3* |
2.2 |
0.0 |
5.0 |
0.0 |
|
| (0.3-7.7) |
(0.0-4.2) |
(1.0-13.9) |
(0.0-7.9) |
||
|
Redness |
Any |
6.6 |
12.9 |
10.0 |
6.7 |
| (2.5-13.8) |
(6.6-22.0) |
(3.8-20.5) |
(1.4-18.3) |
||
| >100 mm |
0.0 |
0.0 |
3.3 |
2.2 |
|
| (0.0-4.0) |
(0.0-4.2) |
(0.4-11.5) |
(0.1-11.8) |
||
| Swelling | Any |
8.8 |
11.8 |
16.7 |
8.9 |
| (3.9-16.6) |
(5.8-20.6) |
(8.3-28.5) |
(2.5-21.2) |
||
| >100 mm |
0.0 |
0.0 |
0.0 |
0.0 |
|
| (0.0-4.0) | (0.0-4.2) | (0.0-6.0) | (0.0-7.9) | ||
*Grade 3 was defined as significant injection site pain at rest which prevents normal activities (inability to attend/do work).